Tuesday, August 04, 2020 5:19:47 PM
https://finance.yahoo.com/news/edited-transcript-lnth-oq-earnings-121431193.html
"Turning now to Flurpiridaz F 18, our novel PET cardiac imaging agent. Our development and commercialization partner, GE Healthcare, has informed us that the second Phase III trial continues. However, new patient enrollment has been delayed due to the impact of the pandemic. GE Healthcare intends to resume enrollment in this quarter and expects to complete enrollment by mid-2021, and, assuming regulatory approval, begin commercialization in early 2023."
"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM